M. Loncá

发表

Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART

F. Figueras, M. Palacio, S. Hernández, 2012, AIDS.

High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir

T. Pumarola, J. Gatell, A. León, 2005, AIDS.

Zidovudine treatment in HIV-infected pregnant women is associated with fetal cardiac remodelling

B. Bijnens, E. Gratacós, F. Crispi, 2016, AIDS.

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1–Infected Patients Starting Efavirenz, Lopinavir–Ritonavir, or Atazanavir–Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial)

D. Podzamczer, B. Clotet, M. Plana, 2015, Journal of acquired immune deficiency syndromes.

Intrathoracic fat in HIV‐infected patients

A. León, J. Mallolas, M. Larrousse, 2006, HIV medicine.

A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression

D. Podzamczer, B. Clotet, J. Miro, 2009, Journal of acquired immune deficiency syndromes.

Risk of intrauterine growth restriction among HIV-infected pregnant women: a cohort study

E. Gratacós, F. Figueras, M. Palacio, 2014, European Journal of Clinical Microbiology & Infectious Diseases.

Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.

D. Podzamczer, M. Plana, A. Cruceta, 2010, AIDS research and human retroviruses.

Fertility assessment in non-infertile HIV-infected women and their partners.

E. Martinez, F. Figueras, M. Palacio, 2007, Reproductive biomedicine online.

The Impact of Reducing Stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients

Ò. Miró, A. León, J. Mallolas, 2006, Antiviral therapy.

Differential Subcutaneous Adipose Tissue Gene Expression Patterns in a Randomized Clinical Trial of Efavirenz or Lopinavir-Ritonavir in Antiretroviral-Naive Patients

E. Negredo, M. Arnedo, E. Martinez, 2014, Antimicrobial Agents and Chemotherapy.

Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir

A. Cruceta, M. Arnedo, M. Loncá, 2016, HIV medicine.

Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy

D. Podzamczer, J. Gatell, E. Martinez, 2012, AIDS.

Clinical, Virologic, and Immunologic Response to Efavirenz-or Protease Inhibitor–Based Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive Patients With Advanced HIV Infection (EfaVIP 2 Study)

J. Gatell, J. Arribas, J. Peña, 2004, Journal of acquired immune deficiency syndromes.

Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers

Ò. Miró, J. Gatell, J. Mallolas, 2019, PloS one.

Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.

J. Gatell, J. Mallolas, E. Martinez, 2014, The Journal of antimicrobial chemotherapy.

Pharmacokinetic Study of Dual Therapy With Raltegravir 400 mg Twice Daily and Darunavir/Ritonavir 800/100 mg Once Daily in HIV-1–Infected Patients

J. Gatell, J. Mallolas, E. Martinez, 2013, Therapeutic drug monitoring.

Inflammatory Markers Related to Microbial Translocation Among HIV-Infected Pregnant Women: A Risk Factor of Preterm Delivery.

E. Gratacós, F. Figueras, M. Palacio, 2016, The Journal of infectious diseases.

Depressive Symptoms after Initiation of Interferon Therapy in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C

Felipe García, J. Miro, J. Gatell, 2004, Antiviral therapy.

Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study.

J. Gatell, A. León, J. Mallolas, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitors.

J. Gatell, J. Mallolas, C. Tortajada, 1997, AIDS.

Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.

J. Gatell, J. Mallolas, E. Martinez, 2016, The Journal of antimicrobial chemotherapy.

Changes in Body Composition and Mitochondrial Dna in HIV-1-Infected Patients Switching to Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine: A Substudy of the Bicombo Trial

D. Podzamczer, J. Gatell, E. Martinez, 2012, Antiviral therapy.

[Current status of acute hepatitis C].

J. Mallolas, E. Martinez, J. Blanco, 2011, Enfermedades infecciosas y microbiologia clinica.

Necrotizing external otitis treated with ciprofloxacin

M. Loncá, J. Mensa, M. Carulla, 1988, The Journal of Laryngology & Otology.

Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients.

J. Gatell, J. Mallolas, E. Martinez, 2012, AIDS research and human retroviruses.

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial

Roger Paredes, Esteban Martinez, Bonaventura Clotet, 2018, The Journal of antimicrobial chemotherapy.

Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy

J. Gatell, A. León, J. Mallolas, 2006, AIDS.

Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients.

J. Gatell, J. Sánchez-Tapias, A. León, 2008, AIDS research and human retroviruses.

Predictive Value of Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients Treated With an Interferon-Based Regimen Plus Ribavirin

J. Gatell, J. Sánchez-Tapias, A. León, 2007, Journal of acquired immune deficiency syndromes.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients

A. León, J. Mallolas, E. Martinez, 2004, AIDS.

Incidence and Risk Factors for Mitochondrial Toxicity in Treated HIV/HCV-Coinfected Patients

Felipe García, J. Miro, J. Gatell, 2005, Antiviral therapy.

A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity

M. Plana, J. Miro, J. Gatell, 2018, AIDS.

Prenatal diagnosis in human immunodeficiency virus-infected women: a new screening program for chromosomal anomalies.

S. Hernández, O. Coll, A. Borrell, 2006, American journal of obstetrics and gynecology.

Decreased pregnancy rate after in-vitro fertilization in HIV-infected women receiving HAART

J. Gatell, E. Martinez, F. Figueras, 2006, AIDS.

Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations

T. Pumarola, J. Gatell, A. León, 2006, AIDS.

Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection

W. Rozenbaum, N. Clumeck, F. Castelli, 1996, AIDS.

Risk of intrauterine growth restriction among HIV-infected pregnant women: a cohort study

E. Gratacós, F. Figueras, M. Palacio, 2015, European Journal of Clinical Microbiology & Infectious Diseases.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Tolerability of integrase inhibitors in a real-life setting

J. Gatell, J. Blanch, J. Mallolas, 2017, The Journal of antimicrobial chemotherapy.

Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial.

B. Clotet, E. Negredo, Felipe García, 2014, AIDS research and human retroviruses.

Pharmacokinetic Study of Saquinavir 500 mg Plus Ritonavir (1000/100 mg Twice a Day) in HIV-Positive Pregnant Women

J. Mallolas, E. Martinez, J. Blanco, 2011, Therapeutic Drug Monitoring.

Current guidelines on management of HIV-infected pregnant women: impact on mode of delivery.

S. Hernández, O. Coll, Marta López, 2008, European journal of obstetrics, gynecology, and reproductive biology.

Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues.

A. León, J. Mallolas, E. Martinez, 2007, The Journal of antimicrobial chemotherapy.

Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir / ritonavircontaining ritonavircontaining ritonavircontaining therapy free of thymidine analogues

A. León, J. Mallolas, E. Martinez, 2007 .

[Acute outbreak of hepatitis C in human immunodeficiency virus-infected patients].

J. Gatell, J. Mallolas, E. Martinez, 2015, Enfermedades infecciosas y microbiologia clinica.

Incidence and causes of death in HIV‐infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area

A. León, J. Mallolas, M. Laguno, 2007, HIV medicine.

Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor

Felipe García, M. Arnedo, T. Pumarola, 2005, AIDS.

A 24-week pilot study of dual maintenance therapy with raltegravir plus lamivudine.

M. Plana, J. Blanch, J. Mallolas, 2019, AIDS.

Impact of Prior Virological Failure and Nucleos(t)ide Genotypic Resistance Mutations on the Efficacy of Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir

D. Podzamczer, J. Mallolas, E. Martinez, 2015, Antiviral therapy.

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction

D. Podzamczer, J. Gatell, J. Mallolas, 2010, AIDS.

High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients).

J. Gatell, J. Arribas, J. Peña, 2002, AIDS.

Noninvasive Diagnosis of Hepatic Fibrosis in HIV/HCV-Coinfected Patients

J. Miro, J. Gatell, A. León, 2007, Journal of acquired immune deficiency syndromes.

Human Papillomavirus Infection in HIV-1 Infected Women in Catalonia (Spain): Implications for Prevention of Cervical Cancer

S. de Sanjosé, B. Lloveras, G. Sirera, 2012, PloS one.

Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine: 96-Week Results of a Randomized Study

D. Podzamczer, J. Gatell, J. Niubó, 2007, Journal of acquired immune deficiency syndromes.

Pregnancy in a Renal Transplant Recipient with HIV-1 Infection: A Case Report

J. Miro, J. Campistol, F. Oppenheimer, 2016, Antiviral therapy.

D. Podzamczer, X. Badia, J. Gatell, 2004, Antiviral therapy.

Low-Density Lipoprotein Size and Lipoprotein-Associated Phospholipase A2 in HIV-Infected Patients Switching to Abacavir or Tenofovir

D. Podzamczer, E. Negredo, J. Gatell, 2011, Antiviral therapy.

Subclinical cardiovascular disease in patients starting contemporary protease inhibitors

J. Mallolas, M. Loncá, M. Camafort, 2018, HIV medicine.